Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis (Q62818096)
Jump to navigation
Jump to search
scientific article published on 16 November 2017
Language | Label | Description | Also known as |
---|---|---|---|
English | Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis |
scientific article published on 16 November 2017 |
Statements
Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis (English)
A Pardanani
J Gotlib
M Wadleigh
S Sirhan
J Kawashima
J A Maltzman
L Shao
V Gupta
16 November 2017